InvestSMART

Argenica Therapeutics Limited (ASX:AGN)

ALERT: Price-sensitive ASX Announcement for AGN
Current share price for AGN : $0.165 0 (0%)+
Announcement
Release
26 Mar 2026 8:13AM
Price at Release
$0.165
Full Release
download
Summary
Argenica Therapeutics Limited, a biotechnology company focused on neuroprotective therapeutics, has been recognized for its high-quality research with the acceptance of two presentations at the European Stroke Organisation Conference in May 2026. The presentations, one oral and one poster, focus on the Phase II trial of their lead drug candidate, ARG-007, for acute ischaemic stroke patients. These presentations have been acknowledged for their impact, with the poster being a Best Poster Finalist, underscoring the scientific significance and potential impact of their work.
Key Points
  • Argenica Therapeutics Limited announced two abstracts selected for presentation at the European Stroke Organisation Conference.
  • The first presentation is an oral presentation on the Phase II ARG-007-002 SEANCON trial of ARG-007 in stroke patients.
  • The second presentation is a poster presentation focusing on larger infarct cores and functional outcomes.
  • The poster is a Best Poster Finalist, highlighting its scientific quality and potential impact.
  • Both presentations are embargoed until the conference in May 2026.
  • Dr. Liz Dallimore highlighted the recognition of Argenica's work as indicative of the trial's quality and impact.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.